☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
apellis
Apellis Presented P-III (GALE) Extension Study Results of Syfovre for Geographic Atrophy at ASRS 2023
August 1, 2023
PharmaShots Weekly Snapshots (April 24 - 28, 2023)
April 28, 2023
Apellis Presents P-III Studies (OAKS) and (DERBY) Results of Syfovre (pegcetacoplan) in Patients with Geographic Atrophy at ARVO 2...
April 24, 2023
Apellis’ Syfovre Receives the US FDA’s Approval as the First Treatment for Geographic Atrophy
February 21, 2023
Apellis Presents 24-Month P-III (OAKS) Post Hoc Results of Pegcetacoplan for the Treatment of Geographic Atrophy at AAO 2022
October 3, 2022
Apellis Reports P-III (DERBY) and (OAKS) Studies Results of Pegcetacoplan for Geographic Atrophy
August 25, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.